$ATAI

HERSHBERG ROBERT sold $496K of ATAI

HERSHBERG ROBERT sold 100,000 shares of AtaiBeckley Inc. (ATAI) at $4.96 ($0.50M total) on 2026-07-07 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · HERSHBERG ROBERT
Published Jul 9, 2026, 9:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 9, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ATAI
Neutral
high confidence
Mentioned
$ATAI
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ATAINeutralLow
01

Why it matters

This is a disclosed insider transaction with no accompanying new corporate event (no earnings, trial result, guidance, or deal). The main tradable element is potential sentiment around insider selling, tempered by the stated 10b5-1 plan.

02

Market read

Traders may note the sale for sentiment, but it is unlikely to change valuation without additional fundamental catalysts.

03

What to watch

The article does not state whether other insiders or the company have concurrent transactions, nor does it provide context on total holdings or prior sale cadence.

Relevance 3/10Novelty 2/10Timing: Filed 2026-07-09 after-hours; reflects sale executed 2026-07-07.

Background

The article is a SEC Form 4 disclosure of an insider open-market sale by a director of AtaiBeckley Inc.

Company-level read

Ticker impact

$ATAINeutralHigh confidence
Context

AtaiBeckley director Robert Hershberg sold 100,000 shares at $4.96 on 2026-07-07 under a pre-arranged 10b5-1 plan.

Expected impact

Likely limited, short-lived impact; any move would be more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new company-specific performance or guidance data.

Market effects

Minimal read-across to biotech sector fundamentals; this is an individual insider liquidity event.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may not signal bearish expectations and could be interpreted as planned diversification rather than concern.

Key entities

  • AtaiBeckley Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Hershberg Robert

    Director who sold 100,000 shares under a pre-arranged 10b5-1 plan.

Related articles

$LLYMedAI 8/10

Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.

Eli Lilly agreed to acquire AtaiBeckley for $2.8 billion upfront, with up to $1 billion in milestone payments, according to the companies. Ark Genomic Revolution ETF sold Atai shares and bought Compass Pathways shares. The article cites Jefferies estimates of $1-2 billion peak sales for Atai’s BPL-003 and notes Compass’s COMP360 phase 3 results and potential 2026 NDA timing.

$LLYMedAI 8/10

Eli Lilly Is Acquiring AtaiBeckley for $2.8 Billion. Cathie Wood Thinks Another Psychedelic Drug Stock Is an Even Better Bet.

Eli Lilly agreed to acquire AtaiBeckley for $2.8 billion upfront, with up to $1 billion in milestone payments, according to the companies. Atai’s lead drug BPL-003 is in phase 3 for treatment-resistant depression, with Jefferies estimating peak sales of $1 billion to $2 billion. The article also notes Ark Genomic Revolution ETF trading in Atai and Compass, and highlights regulatory changes affecting psychedelic reviews.

$LLYMedAI 8/10

Eli Lilly’s Psychedelic Treatment-Resistant Depression Play

Eli Lilly plans to acquire AtaiBeckley to expand its neuroscience pipeline, including rapid-acting neuroplastogens for treatment-resistant depression. The deal could be worth up to $3.8bn. AtaiBeckley’s lead candidate BPL-003 (mebufotenin benzoate) is in Phase 3 and has FDA Breakthrough Therapy Designation. Lilly also agreed deals for Centessa ($7.8bn) and Kelonia Therapeutics ($7bn).

$LLYHighAI 9/10

Lilly to acquire AtaiBeckley in deal worth $2.8bn

Eli Lilly agreed to acquire AtaiBeckley in a $2.8bn deal. AtaiBeckley develops rapid-acting neuroplastogens for mental health, led by BPL-003 (mebufotenin benzoate) for treatment-resistant depression. Lilly says BPL-003 showed rapid, durable symptom reductions in a phase 2b study and has FDA Breakthrough Therapy Designation, with phase 3 activities underway.